中华妇幼临床医学杂志（电子版）
中華婦幼臨床醫學雜誌（電子版）
중화부유림상의학잡지（전자판）
Chinese Journal of Obstetrics & Gynecology and Pediatrics (Electronic Edition)
2015年
5期
605-608
,共4页
孟鲁司特钠%干扰素α1b%药物疗法,联合%支气管炎%哮喘%治疗结果
孟魯司特鈉%榦擾素α1b%藥物療法,聯閤%支氣管炎%哮喘%治療結果
맹로사특납%간우소α1b%약물요법,연합%지기관염%효천%치료결과
Montelukast sodium%Interferon α1b%Drug therapy,combination%Bronchitis%Asthma%Treatment outcomes
目的：探讨孟鲁司特钠联合干扰素α1b 治疗小儿喘息性支气管炎(AB)的临床效果。方法选择2013年4月至2014年4月于武汉市第八医院诊治的80例小儿 AB 患者为研究对象,按照入院顺序单、双号,将其随机分为实验组(n=40)和对照组(n =40)。入选患儿均符合小儿 AB 临床诊断标准。同时排除伴有药物过敏史及肝、肾功能不全者。实验组患儿采用孟鲁司特钠联合干扰素α1b 方案治疗,对照组采用常规方案治疗。对两组患儿的治疗有效率、满意率及住院时间等进行统计学分析。本研究遵循的程序符合武汉市第八医院人体试验委员会所制定的伦理学标准,得到该委员会批准,分组征得受试对象监护人的知情同意,并与之签署临床研究知情同意书。两组患儿性别、年龄及病程等一般临床资料比较,差异均无统计学意义(P >0.05)。结果实验组治疗有效率、满意率分别为95.0%与97.5%,显著优于对照组的80.0%与77.5%,且差异均有统计学意义(χ2=4.114,7.314,P <0.05)；实验组患儿住院时间、喘憋症状消失时间、发热消失时间及哮鸣音消失时间分别为(12.8±6.7)d,(1.6±1.1)d,(1.7±0.1)d 及(5.5±1.5)d,均显著短于对照组的(15.5±5.8)d,(7.8±2.5)d,(3.3±1.0)d 及(9.2±3.2)d,两组上述观察指标分别比较,差异均有统计学意义(t=4.28,5.78,5.55,12.31,P <0.05)。实验组治疗相关不良反应发生率为0,低于对照组的5%,但差异无统计学意义(χ2=0.51,P >0.05)。结论目前,小儿 AB 发病率较高,临床上采用孟鲁司特钠联合干扰素α1b 治疗效果理想,但是否值得临床推广应用,尚需多中心、大样本随机对照研究进一步证实。
目的：探討孟魯司特鈉聯閤榦擾素α1b 治療小兒喘息性支氣管炎(AB)的臨床效果。方法選擇2013年4月至2014年4月于武漢市第八醫院診治的80例小兒 AB 患者為研究對象,按照入院順序單、雙號,將其隨機分為實驗組(n=40)和對照組(n =40)。入選患兒均符閤小兒 AB 臨床診斷標準。同時排除伴有藥物過敏史及肝、腎功能不全者。實驗組患兒採用孟魯司特鈉聯閤榦擾素α1b 方案治療,對照組採用常規方案治療。對兩組患兒的治療有效率、滿意率及住院時間等進行統計學分析。本研究遵循的程序符閤武漢市第八醫院人體試驗委員會所製定的倫理學標準,得到該委員會批準,分組徵得受試對象鑑護人的知情同意,併與之籤署臨床研究知情同意書。兩組患兒性彆、年齡及病程等一般臨床資料比較,差異均無統計學意義(P >0.05)。結果實驗組治療有效率、滿意率分彆為95.0%與97.5%,顯著優于對照組的80.0%與77.5%,且差異均有統計學意義(χ2=4.114,7.314,P <0.05)；實驗組患兒住院時間、喘憋癥狀消失時間、髮熱消失時間及哮鳴音消失時間分彆為(12.8±6.7)d,(1.6±1.1)d,(1.7±0.1)d 及(5.5±1.5)d,均顯著短于對照組的(15.5±5.8)d,(7.8±2.5)d,(3.3±1.0)d 及(9.2±3.2)d,兩組上述觀察指標分彆比較,差異均有統計學意義(t=4.28,5.78,5.55,12.31,P <0.05)。實驗組治療相關不良反應髮生率為0,低于對照組的5%,但差異無統計學意義(χ2=0.51,P >0.05)。結論目前,小兒 AB 髮病率較高,臨床上採用孟魯司特鈉聯閤榦擾素α1b 治療效果理想,但是否值得臨床推廣應用,尚需多中心、大樣本隨機對照研究進一步證實。
목적：탐토맹로사특납연합간우소α1b 치료소인천식성지기관염(AB)적림상효과。방법선택2013년4월지2014년4월우무한시제팔의원진치적80례소인 AB 환자위연구대상,안조입원순서단、쌍호,장기수궤분위실험조(n=40)화대조조(n =40)。입선환인균부합소인 AB 림상진단표준。동시배제반유약물과민사급간、신공능불전자。실험조환인채용맹로사특납연합간우소α1b 방안치료,대조조채용상규방안치료。대량조환인적치료유효솔、만의솔급주원시간등진행통계학분석。본연구준순적정서부합무한시제팔의원인체시험위원회소제정적윤리학표준,득도해위원회비준,분조정득수시대상감호인적지정동의,병여지첨서림상연구지정동의서。량조환인성별、년령급병정등일반림상자료비교,차이균무통계학의의(P >0.05)。결과실험조치료유효솔、만의솔분별위95.0%여97.5%,현저우우대조조적80.0%여77.5%,차차이균유통계학의의(χ2=4.114,7.314,P <0.05)；실험조환인주원시간、천별증상소실시간、발열소실시간급효명음소실시간분별위(12.8±6.7)d,(1.6±1.1)d,(1.7±0.1)d 급(5.5±1.5)d,균현저단우대조조적(15.5±5.8)d,(7.8±2.5)d,(3.3±1.0)d 급(9.2±3.2)d,량조상술관찰지표분별비교,차이균유통계학의의(t=4.28,5.78,5.55,12.31,P <0.05)。실험조치료상관불량반응발생솔위0,저우대조조적5%,단차이무통계학의의(χ2=0.51,P >0.05)。결론목전,소인 AB 발병솔교고,림상상채용맹로사특납연합간우소α1b 치료효과이상,단시부치득림상추엄응용,상수다중심、대양본수궤대조연구진일보증실。
Objective To study clinical effect of montelukast sodium combined with interferon α1b in treatment of pediatric asthmatic bronchitis (AB).Methods From April 2013 to April 2014,a total of 80 cases of children with AB who hospitalized in the Eighth Hospital of Wuhan City were admitted as research objects.According to their odd and even number of admission, they were randomly divided into experimental group (n=40)and control group (n=40).All the patients were in accordance with the clinical diagnostic criteria of AB,and the patients who had the history of drug allergy,liver and renal insufficiency were excluded.In experimental group,the patients were treated with montelukast sodium combined with interferon α1b, while control group was treated with routine method. The treatment effective rate, satisfaction degree and hospitalization time,etc.between two groups were statistically analyzed.The procedure that this study followed met the ethical standards made by Institutional Review Board of the Eighth Hospital of Wuhan City in Hebei Province and approved by the committee.Grouping had the consent of guardians of study subjects and clinical study letter of consent was signed.The differences in age,gender ratio, course of disease and other general clinical data of the patients between two groups were not statistically significant (P >0.05).Results The effective rate and the treatment satisfaction of guardians of study subjects in experimental group were 95.0% and 97.5% which were significantly better than 80.0%and 77.5% of control group,there were significant differences between two groups(χ2 =4.1 14,7.314;P <0.05).The hospitalization time,wheezing symptoms disappearance time,fever disappearing time and wheeze disappearing time of experimental group were (12.8±6.7)d ,(1.6±1.1)d,(1.7±0.1)and (5.5±1.5)d which were significance shorter than those (1 5.5±5.8)d,(7.8±2.5)d ,(3.3±1.0)d and (9.2±3.2)d in control group,respectively ,and there were significant differences between two groups (t =4.28,5.78, 5.55,12.31;P <0.05).The incidence rate of adverse reactions after treatment in experimental group and control group were 0 and 5% respectively,and there was no statistical significance between them (χ2 =0.5 1,P >0.05).Conclusions At present,the incidence rate of AB in children is high,and the treatment effect of strategy of montelukast sodium combined with interferonα1b is ideal.Whether montelukast sodium combined with interferon α1b in treating pediatric AB is worthy of clinical promotion and application or not, it still needs to be further confirmed by randomized controlled trials of multiple centers and large samples.
